Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:50 UTC |
---|
Update Date | 2022-03-07 02:51:45 UTC |
---|
HMDB ID | HMDB0014812 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Galantamine |
---|
Description | Galantamine, also known as reminyl or nivalin, belongs to the class of organic compounds known as galanthamine-type amaryllidaceae alkaloids. These are amaryllidaceae alkaloids with a structure characterized a tetracyclic skeleton with two ortho aromatic protons in ring A. Galantamine is a drug which is used for the treatment of mild to moderate dementia of the alzheimer's type. has also been investigated in patients with mild cognitive impairment who did not meet the diagnostic criteria for alzheimer's disease. Galantamine is a very strong basic compound (based on its pKa). Galantamine is a potentially toxic compound. A benzazepine alkaloid isolated from certain species of daffodils. |
---|
Structure | [H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3 InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1 |
---|
Synonyms | Value | Source |
---|
(-)-GALANTHAMINE | ChEBI | Reminyl | Kegg | Galanthamine | HMDB | Galanthamine hydrobromide | HMDB | Lycoremine | HMDB | Galantamin | HMDB | Razadyne | HMDB | Nivalin | HMDB | Nivaline | HMDB | Ortho mcneil neurologics brand OF galantamine | HMDB | Ortho-mcneil neurologics brand OF galantamine | HMDB | Galantamine | ChEBI |
|
---|
Chemical Formula | C17H21NO3 |
---|
Average Molecular Weight | 287.3535 |
---|
Monoisotopic Molecular Weight | 287.152143543 |
---|
IUPAC Name | (1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6(17),7,9,15-tetraen-14-ol |
---|
Traditional Name | galantamine |
---|
CAS Registry Number | 357-70-0 |
---|
SMILES | [H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3 |
---|
InChI Identifier | InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1 |
---|
InChI Key | ASUTZQLVASHGKV-JDFRZJQESA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as galanthamine-type amaryllidaceae alkaloids. These are amaryllidaceae alkaloids with a structure characterized a tetracyclic skeleton with two ortho aromatic protons in ring A. |
---|
Kingdom | Organic compounds |
---|
Super Class | Alkaloids and derivatives |
---|
Class | Amaryllidaceae alkaloids |
---|
Sub Class | Galanthamine-type amaryllidaceae alkaloids |
---|
Direct Parent | Galanthamine-type amaryllidaceae alkaloids |
---|
Alternative Parents | |
---|
Substituents | - Galanthamine-type amaryllidaceae alkaloid
- Benzazepine
- Coumaran
- Anisole
- Alkyl aryl ether
- Azepine
- Aralkylamine
- Benzenoid
- Secondary alcohol
- Tertiary amine
- Tertiary aliphatic amine
- Ether
- Oxacycle
- Organoheterocyclic compound
- Azacycle
- Amine
- Organic nitrogen compound
- Alcohol
- Organooxygen compound
- Organonitrogen compound
- Hydrocarbon derivative
- Organopnictogen compound
- Organic oxygen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 269 - 270 °C (hydrogen bromide salt) | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 1.7 g/L | Not Available | LogP | 1.8 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatized | Show more...
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Galantamine GC-MS (Non-derivatized) - 70eV, Positive | splash10-010u-2090000000-ce0fee33e6fee456fb64 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Galantamine GC-MS (1 TMS) - 70eV, Positive | splash10-00fu-9137000000-e759a1bc34f489765011 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Galantamine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-000l-5980000000-928ad889466b6a2b3827 | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Galantamine , positive-QTOF | splash10-000i-0390000000-f4f443a7f842d92dec39 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Galantamine 35V, Positive-QTOF | splash10-03ei-0390000000-5f20c8cd1421554a2365 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Galantamine 10V, Positive-QTOF | splash10-00dr-0090000000-c09fea1137eb040ccff3 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Galantamine 20V, Positive-QTOF | splash10-00dr-1090000000-e8fc73122c750f4a8b29 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Galantamine 40V, Positive-QTOF | splash10-1000-4190000000-4e6f34da3d49bbf029b4 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Galantamine 10V, Negative-QTOF | splash10-000i-0090000000-d57ff615302227895e9b | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Galantamine 20V, Negative-QTOF | splash10-000i-0090000000-084d311da94f251627eb | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Galantamine 40V, Negative-QTOF | splash10-0w2c-1490000000-3ee999f09979ab3820f1 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Galantamine 10V, Positive-QTOF | splash10-000i-0090000000-8e23f9bfe8905382513a | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Galantamine 20V, Positive-QTOF | splash10-0079-0090000000-a9adf4464f8392bb18ad | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Galantamine 40V, Positive-QTOF | splash10-000l-1090000000-cd82eceaf8d38fd37298 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Galantamine 10V, Negative-QTOF | splash10-000i-0090000000-32affc6af32f5da1d257 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Galantamine 20V, Negative-QTOF | splash10-000i-0090000000-6b6acbca4d5713d4973f | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Galantamine 40V, Negative-QTOF | splash10-02u3-0090000000-5c86743e445ac6cabb6a | 2021-10-11 | Wishart Lab | View Spectrum |
| Show more...
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00674 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00674 | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB00674 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | C00001570 |
---|
Chemspider ID | 9272 |
---|
KEGG Compound ID | C08526 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Galantamine |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 9651 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 42944 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL: Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999 Dec 17;463(3):321-6. [PubMed:10606746 ]
- Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632 ]
- Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124 ]
- Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. [PubMed:16437532 ]
- Woodruff-Pak DS, Vogel RW 3rd, Wenk GL: Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):2089-94. Epub 2001 Feb 6. [PubMed:11172080 ]
|
---|